AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER
Sep 062013
 

This Biotech Has So Many Reasons to Be Liked
Motley Fool
With promising mid-stage results, the drug is expected to do well in phase 3 evaluation for pancreatic cancer.

Positive phase 3 results will open the door to the lucrative pancreatic cancer market, on top of the myelofibrosis market that is expected to

READ ALL AT

http://www.fool.com/investing/general/2013/09/05/this-biotech-has-so-many-reasons-to-be-liked.aspx

Share

Sorry, the comment form is closed at this time.

Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: